As Hong Kong’s population ages, the need for therapies to treat degenerative joint conditions is increasing. Statistics show that in Hong Kong, 17 percent of men and 24 percent of women aged 50 or above suffer joint pain problems. Non-surgical treatments such as hyaluronic acid or steroid injections may not be suitable for all patients, and surgical procedures often involve longer waiting times. Research has found that Mesenchymal Stem Cells (MSC) can facilitate tissue repair in degenerated joints, offering new treatment options.
Hong Kong Regen Medtech Limited (HKRM) and Cordlife Hong Kong have signed a collaboration agreement to implement a regenerative medicine project focusing on degenerative joint disease using mesenchymal stem cells. The announcement was made at a media briefing at Science Park on July 21.
